Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Correction to: Cancer Chemotherapy and Pharmacology 10.1007/s00280-021-04296-0

In the original publication, there were errors in some sentences that are corrected as below:

In the keywords section, Page 1, Lines 1–2: the “Pertuzumab”, “Trastuzumab”, and “Hyaluronidase-zzxf” should all be replaced with “Pertuzumab, trastuzumab, and hyaluronidase-zzxf”.

In the Introduction section, Page 2, Paragraph 3, Lines 10–11: “(C_trough and area under the curve [AUC])” should be replaced with “[C_trough and area under the curve (AUC)]”.

In the Introduction section, Page 2, Paragraph 3, Lines 18–19: “2000 U/mL” currently spans over two lines; it should be on the same line.

In the Materials and methods section, Study design, Lines 9–13: “(4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of doxorubicin plus cyclophosphamide (AC) every 3 weeks followed by 4 cycles of docetaxel every 3 weeks)” should be replaced with “[4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of doxorubicin plus cyclophosphamide (AC) every 3 weeks followed by 4 cycles of docetaxel every 3 weeks]”.

In the Materials and methods section, Procedures, Paragraph 1, Lines 11–12: “HER2-targeted” currently spans over two lines; it should be on the same line.

In the Materials and methods section, Procedures, Paragraph 1, Lines 12–13: “P IV” currently spans over two lines; it should be on the same line.

In the Materials and methods section, Pertuzumab population pharmacokinetic analysis, Paragraph 2, Lines 13–19: “[hormone receptor status (estrogen receptor- or progesterone receptor-positive, or estrogen receptor- and progesterone receptor-negative), clinical stage (II–IIIA or IIIB–IIIC), and chemotherapy regimen (4 cycles of ddAC every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of AC every 3 weeks followed by 4 cycles of docetaxel every 3 weeks]” should be replaced with “[hormone receptor status (estrogen receptor- or progesterone receptor-positive, or estrogen receptor- and progesterone receptor-negative), clinical stage (II–IIIA or IIIB–IIIC), and chemotherapy regimen (4 cycles of ddAC every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of AC every 3 weeks followed by 4 cycles of docetaxel every 3 weeks)]”.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 18: “(F)” should be replaced with “(F)”, i.e., ‘F’ in italics.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 19: “CL (L/days) =0.163” should be replaced with “CL (L/days) = 0.163”, i.e., a space inserted after the equals sign.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 20: “× (1.123if” should be replaced with “× (1.123 if”, i.e., a space inserted after the ‘1.123’.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 21: “V_c” should be replaced with “V_c”, i.e., ‘_c’ in italics.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 5, Paragraph 1, Line 1: “Q(L/days)” should be replaced with “ Q (L/days)”, i.e., a space inserted after the ‘Q’.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 5, Paragraph 1, Line 2: “V_p” should be replaced with “V_p”, i.e., ‘_p’ in italics.

In the Results section, Pertuzumab population pharmacokinetic analysis, Page 5, Paragraph 1, Lines 1–3:

“(Q, L/days) = 0.616,

$$V_{\text{p}}\left(\text{L}\right)=2.49\times {\left(\text{LBW}/45.09\right)}^{0.716}\times e^{\eta V3},$$

$$F=0.712\times e^{\eta F}.$$

” should be moved up to the previous page to keep all equations together.

In the Results section, Exposure–safety of PH FDC SC, Paragraph 1, Lines 7–8: “grade ≥ 3” currently spans over two lines; it should be on the same line.

In the Declarations section, Conflict of interest, Lines 8–9: “Stephanie Hennig” currently spans over two lines; it should be on the same line.

The authors sincerely apologize for any inconvenience caused by these errors.

The original article has been corrected.